Lac-regulated system for generating adenovirus 5 vaccine vectors expressing cytolytic human immunodeficiency virus 1 genes

Journal of Virological Methods

Volumn 160, Issue 1-2, 2009, Pages 101-110

  Zhao, Chunxia ^a   Crews, Charles Jefferson ^a   Derdeyn, Cynthia A ^a,b   Blackwell, Jerry L ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Env; Glycoprotein; HIV 1; Lac repressor operator

Indexed keywords

ADENOVIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LUCIFERASE; VIRUS ENVELOPE PROTEIN;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENETICS; VIRUS GENE;

ADENOVIRUSES, HUMAN; AIDS VACCINES; CELL LINE; GENE EXPRESSION; GENETIC VECTORS; GENOMIC INSTABILITY; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; LAC OPERON; PROMOTER REGIONS, GENETIC;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS); HUMAN ADENOVIRUS TYPE 5; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67549132505     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2009.04.028     Document Type: Article

References (80)

1. Addison C.L., Hitt M., Kunsken D., and Graham F.L. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J. Gen. Virol. 78 Pt 7 (1997) 1653-1661
2. Andreau K., Perfettini J.L., Castedo M., Metivier D., Scott V., Pierron G., and Kroemer G. Contagious apoptosis facilitated by the HIV-1 envelope: fusion-induced cell-to-cell transmission of a lethal signal. J. Cell. Sci. 117 (2004) 5643-5653
3. Aoki K., Akyurek L.M., San H., Leung K., Parmacek M.S., Nabel E.G., and Nabel G.J. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. Mol. Ther. 1 (2000) 555-565
4. Barouch D.H., and Nabel G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther. 16 (2005) 149-156
5. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., Truitt D.M., Sumida S.M., Kishko M.G., Arthur J.C., Korioth-Schmitz B., Newberg M.H., Gorgone D.A., Lifton M.A., Panicali D.L., Nabel G.J., Letvin N.L., and Goudsmit J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172 (2004) 6290-6297
6. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 (2004) 13232-13252
7. Blackwell J.L., Li H., Gomez-Navarro J., Dmitriev I., Krasnykh V., Richter C.A., Shaw D.R., Alvarez R.D., Curiel D.T., and Strong T.V. Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. Hum. Gene Ther. 11 (2000) 1657-1669
8. Blackwell J.L., Miller C.R., Douglas J.T., Li H., Reynolds P.N., Carroll W.R., Peters G.E., Strong T.V., and Curiel D.T. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 125 (1999) 856-863
9. Blish C.A., Nguyen M.A., and Overbaugh J. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med. 5 (2008) e9
10. Braciak T.A., Gallichan W.S., Graham F.L., Richards C.D., Ramsay A.J., Rosenthal K.L., and Gauldie J. Recombinant adenovirus vectors expressing interleukin-5 and -6 specifically enhance mucosal immunoglobulin A responses in the lung. Immunology 101 (2000) 388-396
11. Bruder J.T., Appiah A., Kirkman III W.M., Chen P., Tian J., Reddy D., Brough D.E., Lizonova A., and Kovesdi I. Improved production of adenovirus vectors expressing apoptotic transgenes. Hum. Gene Ther. 11 (2000) 139-149
12. Bukczynski J., Wen T., Ellefsen K., Gauldie J., and Watts T.H. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 1291-1296
13. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., and Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 (2004) 233-236
14. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., Gu L., Martin J.E., Novik L., Chakrabarti B.K., Butman B.T., Gall J.G., King C.R., Andrews C.A., Sheets R., Gomez P.L., Mascola J.R., Nabel G.J., and Graham B.S. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194 (2006) 1638-1649
15. Chakrabarti B.K., Kong W.P., Wu B.Y., Yang Z.Y., Friborg J., Ling X., King S.R., Montefiori D.C., and Nabel G.J. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol. 76 (2002) 5357-5368
16. Cicala C., Arthos J., Rubbert A., Selig S., Wildt K., Cohen O.J., and Fauci A.S. HIV-1 envelope induces activation of caspase-3 and cleavage of focal adhesion kinase in primary human CD4(+) T cells. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 1178-1183
17. de Gruijl T.D., Luykx-de Bakker S.A., Tillman B.W., van den Eertwegh A.J., Buter J., Lougheed S.M., van der Bij G.J., Safer A.M., Haisma H.J., Curiel D.T., Scheper R.J., Pinedo H.M., and Gerritsen W.R. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J. Immunol. 169 (2002) 5322-5331
18. de Souza A.P., Haut L.H., Silva R., Ferreira S.I., Zanetti C.R., Ertl H.C., and Pinto A.R. Genital CD8(+) T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus. Vaccine 25 (2006) 109-116
19. Devitt G., Emerson V., Holtkotte D., Pfeiffer T., Pisch T., and Bosch V. Incorporation of chimeric HIV-SIV-Env and modified HIV-Env proteins into HIV pseudovirions. Virology 361 (2007) 465-471
20. Douglas J.T., Rogers B.E., Rosenfeld M.E., Michael S.I., Feng M., and Curiel D.T. Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol. 14 (1996) 1574-1578
21. Earl P.L., Broder C.C., Long D., Lee S.A., Peterson J., Chakrabarti S., Doms R.W., and Moss B. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68 (1994) 3015-3026
22. Edholm D., Molin M., Bajak E., and Akusjarvi G. Adenovirus vector designed for expression of toxic proteins. J. Virol. 75 (2001) 9579-9584
23. Edwards T.G., Wyss S., Reeves J.D., Zolla-Pazner S., Hoxie J.A., Doms R.W., and Baribaud F. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J. Virol. 76 (2002) 2683-2691
24. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., Giles-Davis W., Wilson J.M., and Ertl H.C. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170 (2003) 1416-1422
25. Ghosh S.S., Gopinath P., and Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl. Biochem. Biotechnol. 133 (2006) 9-29
26. Glasgow J.N., Everts M., and Curiel D.T. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther. 13 (2006) 830-844
27. Graham F., and Prevec L. Manipulation of adenovirus vectors. In: Murray E.J., and Walker J.M. (Eds). Molecular Biology, Gene Transfer and Expression Techniques vol. 7 (1991), Humana Press, Clinton, NJ 109-128
28. Grossman Z., Meier-Schellersheim M., Sousa A.E., Victorino R.M., and Paul W.E. CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause?. Nat. Med. 8 (2002) 319-323
29. Hama S., Akita H., Ito R., Mizuguchi H., Hayakawa T., and Harashima H. Quantitative comparison of intracellular trafficking and nuclear transcription between adenoviral and lipoplex systems. Mol. Ther. 13 (2006) 786-794
30. Haughey N.J., and Mattson M.P. Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J. Acquir. Immune Defic. Syndr. 31 Suppl. 2 (2002) S55-61
31. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 2509-2514
32. Hidaka Y., Hayashi Y., Fisfalen M.E., Suzuki S., Takeda T., Refetoff S., and DeGroot L.J. Expression of thyroid peroxidase in EBV-transformed B cell lines using adenovirus. Thyroid 6 (1996) 23-28
33. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., and Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 (1995) 123-126
34. Hu S.X., Ji W., Zhou Y., Logothetis C., and Xu H.J. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Res. 57 (1997) 3339-3343
35. Jacob F., and Monod J. Genetic regulatory mechanisms in the synthesis of proteins. J. Mol. Biol. 3 (1961) 318-356
36. Kanerva A., Mikheeva G.V., Krasnykh V., Coolidge C.J., Lam J.T., Mahasreshti P.J., Barker S.D., Straughn M., Barnes M.N., Alvarez R.D., Hemminki A., and Curiel D.T. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 8 (2002) 275-280
37. Kasono K., Blackwell J.L., Douglas J.T., Dmitriev I., Strong T.V., Reynolds P., Kropf D.A., Carroll W.R., Peters G.E., Bucy R.P., Curiel D.T., and Krasnykh V. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin. Cancer Res. 5 (1999) 2571-2579
38. Kawakami Y., Li H., Lam J., Krasnykh V., Curiel D.T., and Blackwell J.L. Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res. 63 (2003) 1262-1269
39. Komarova S., Kawakami Y., Stoff-Khalili M.A., Curiel D.T., and Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. 5 (2006) 755-766
40. Krasnykh V.N., Mikheeva G.V., Douglas J.T., and Curiel D.T. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol. 70 (1996) 6839-6846
41. Kresge, K.J., 2007. AIDS Vaccine Trials: '06 Year In Review, VAX, vol. 5, IAVI Report Publication.
42. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P.W., Robinson J., Van Ryk D., Wang L., Burton D.R., Freire E., Wyatt R., Sodroski J., Hendrickson W.A., and Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 (2002) 678-682
43. Lemiale F., Haddada H., Nabel G.J., Brough D.E., King C.R., and Gall J.G. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 25 (2007) 2074-2084
44. Li H., Haviv Y.S., Derdeyn C.A., Lam J., Coolidge C., Hunter E., Curiel D.T., and Blackwell J.L. Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles. Hum. Gene Ther. 12 (2001) 2159-2169
45. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., Wu X., Shaw G.M., Connors M., Wyatt R.T., and Mascola J.R. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13 (2007) 1032-1034
46. Liu X.L., Yu S.Q., Feng X., Wang X.L., Liu H.M., Zhang X.M., Li H.X., Zhou L., Li Z.L., and Zheng Y. Immunogenicity of a chimeric adenovirus type 5 vector with type 35 fiber containing HIV-1 gag in mice. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 21 (2007) 5-7
47. Maizel Jr. J.V., White D.O., and Scharff M.D. The polypeptides of adenovirus. II. Soluble proteins, cores, top components and the structure of the virion. Virology 36 (1968) 126-136
48. Matthews D.A., Cummings D., Evelegh C., Graham F.L., and Prevec L. Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein. J. Gen. Virol. 80 Pt 2 (1999) 345-353
49. McConnell M.J., and Imperiale M.J. Biology of adenovirus and its use as a vector for gene therapy. Hum. Gene Ther. 15 (2004) 1022-1033
50. McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Shih-Wen L., Li Y., Giles-Davis W., Cun A., Zhou D., Xiang Z., Letvin N.L., and Ertl H.C. The effect of pre-existing immunity to antigens of adenovirus of the human serotype 5 on immune responses of nonhuman primates to vaccine regimens based on human or chimpanzee-derived adenovirus vectors. J. Virol. 12 (2007) 6594-6604
51. Meissner E.G., Zhang L., Jiang S., and Su L. Fusion-induced apoptosis contributes to thymocyte depletion by a pathogenic human immunodeficiency virus type 1 envelope in the human thymus. J. Virol. 80 (2006) 11019-11030
52. Mercier G.T., Campbell J.A., Chappell J.D., Stehle T., Dermody T.S., and Barry M.A. A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 6188-6193
53. Mittal S.K., McDermott M.R., Johnson D.C., Prevec L., and Graham F.L. Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res. 28 (1993) 67-90
54. Moffatt S., Hays J., HogenEsch H., and Mittal S.K. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology 272 (2000) 159-167
55. Nanda A., Lynch D.M., Goudsmit J., Lemckert A.A., Ewald B.A., Sumida S.M., Truitt D.M., Abbink P., Kishko M.G., Gorgone D.A., Lifton M.A., Shen L., Carville A., Mansfield K.G., Havenga M.J., and Barouch D.H. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J. Virol. 79 (2005) 14161-14168
56. Pereboev A.V., Asiedu C.K., Kawakami Y., Dong S.S., Blackwell J.L., Kashentseva E.A., Triozzi P.L., Aldrich W.A., Curiel D.T., Thomas J.M., and Dmitriev I.P. Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther. 9 (2002) 1189-1193
57. Pereboev A.V., Nagle J.M., Shakhmatov M.A., Matthews Q.L., Kawakami Y., Curiel D.T., and Blackwell J.L. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol. Ther. 9 (2004) 712-720
58. Perfettini J.L., Castedo M., Roumier T., Andreau K., Nardacci R., Piacentini M., and Kroemer G. Mechanisms of apoptosis induction by the HIV-1 envelope. Cell Death Differ. 12 Suppl. 1 (2005) 916-923
59. Rogers B.E., Douglas J.T., Ahlem C., Buchsbaum D.J., Frincke J., and Curiel D.T. Use of a novel cross-linking method to modify adenovirus tropism. Gene Ther. 4 (1997) 1387-1392
60. Roggero R., Robert-Hebmann V., Harrington S., Roland J., Vergne L., Jaleco S., Devaux C., and Biard-Piechaczyk M. Binding of human immunodeficiency virus type 1 gp120 to CXCR4 induces mitochondrial transmembrane depolarization and cytochrome c-mediated apoptosis independently of Fas signaling. J. Virol. 75 (2001) 7637-7650
61. Rubinchik S., Ding R., Qiu A.J., Zhang F., and Dong J. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther. 7 (2000) 875-885
62. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J. Exp. Med. 205 (2008) 7-12
63. Short J.J., Vasu C., Holterman M.J., Curiel D.T., and Pereboev A. Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res. 122 (2006) 144-153
64. Sirena D., Lilienfeld B., Eisenhut M., Kalin S., Boucke K., Beerli R.R., Vogt L., Ruedl C., Bachmann M.F., Greber U.F., and Hemmi S. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J. Virol. 78 (2004) 4454-4462
65. Sodroski J., Goh W.C., Rosen C., Campbell K., and Haseltine W.A. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 322 (1986) 470-474
66. Steinbrook R. One step forward, two steps back-will there ever be an AIDS vaccine?. N. Engl. J. Med. 357 (2007) 2653-2655
67. Stevenson S.C., Rollence M., Marshall-Neff J., and McClelland A. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J. Virol. 71 (1997) 4782-4790
68. Tekant Y., Davydova J., Ramirez P.J., Curiel D.T., Vickers S.M., and Yamamoto M. Oncolytic adenoviral therapy in gallbladder carcinoma. Surgery 137 (2005) 527-535
69. Thorner A.R., Lemckert A.A., Goudsmit J., Lynch D.M., Ewald B.A., Denholtz M., Havenga M.J., and Barouch D.H. Circumventing vector cross-reactivity enhances the immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens. J. Virol. (2006)
70. Trushin S.A., Algeciras-Schimnich A., Vlahakis S.R., Bren G.D., Warren S., Schnepple D.J., and Badley A.D. Glycoprotein 120 binding to CXCR4 causes p38-dependent primary T cell death that is facilitated by, but does not require cell-associated CD4. J. Immunol. 178 (2007) 4846-4853
71. Vanniasinkam T., and Ertl H.C. Adenoviral gene delivery for HIV-1 vaccination. Curr. Gene Ther. 5 (2005) 203-212
72. Volpers C., Thirion C., Biermann V., Hussmann S., Kewes H., Dunant P., von der Mark H., Herrmann A., Kochanek S., and Lochmuller H. Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J. Virol. 77 (2003) 2093-2104
73. Watkins S.J., Mesyanzhinov V.V., Kurochkina L.P., and Hawkins R.E. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 4 (1997) 1004-1012
74. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
75. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H., Saag M.S., and Shaw G.M. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373 (1995) 117-122
76. Wiethe C., Dittmar K., Doan T., Lindenmaier W., and Tindle R. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. J. Immunol. 171 (2003) 4121-4130
77. Wyatt L.S., Belyakov I.M., Earl P.L., Berzofsky J.A., and Moss B. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology (2007)
78. Xin K.Q., Sekimoto Y., Takahashi T., Mizuguchi H., Ichino M., Yoshida A., and Okuda K. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV. Vaccine 25 (2007) 3809-3815
79. Yao Q.Z., Kuhlmann F.M., Eller R., Compans R.W., and Chen C.Y. Production and characterization of simian-human immunodeficiency virus-like particles. AIDS Res. Hum. Retroviruses 16 (2000) 227-236
80. Yoshida Y., Emi N., and Hamada H. VSV-G-pseudotyped retroviral packaging through adenovirus-mediated inducible gene expression. Biochem. Biophys. Res. Commun. 232 (1997) 379-382